$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000071913523000027 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$13.57M	$12.14M
YoY Change	31.84%	-2.81%
Cost Of Revenue	$4.290M	$4.569M
YoY Change	27.0%	6.9%
Gross Profit	$9.279M	$7.573M
YoY Change	34.21%	-7.86%
Gross Profit Margin	68.38%	62.37%
Selling, General & Admin	$5.378M	$5.255M
YoY Change	18.48%	-3.84%
% of Gross Profit	57.96%	69.39%
Research & Development	$1.199M	$1.121M
YoY Change	12.06%	-3.2%
% of Gross Profit	12.92%	14.8%
Depreciation & Amortization	$151.0K	$203.0K
YoY Change	-38.87%	-9.78%
% of Gross Profit	1.63%	2.68%
Operating Expenses	$13.21M	$13.18M
YoY Change	2.45%	-6.43%
Operating Profit	-$1.235M	-$5.611M
YoY Change	-79.33%	-4.43%
Interest Expense	$543.0K	$234.0K
YoY Change	18000.0%	2825.0%
% of Operating Profit
Other Income/Expense, Net	$282.0K	-$188.0K
YoY Change	-54.66%	596.3%
Pretax Income	-$953.0K	-$5.799M
YoY Change	-82.2%	-1.68%
Income Tax	$66.00K	-$2.267M
% Of Pretax Income
Net Earnings	-$994.0K	-$3.483M
YoY Change	-81.68%	-41.41%
Net Earnings / Revenue	-7.33%	-28.69%
Basic Earnings Per Share	-$0.03	-$0.10
Diluted Earnings Per Share	-$0.03	-$0.10
COMMON SHARES
Basic Shares Outstanding	34.60M shares	34.60M shares
Diluted Shares Outstanding	34.60M shares	34.60M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.48M	$16.25M
YoY Change	-7.9%	-38.04%
Cash & Equivalents	$18.50M	$16.30M
Short-Term Investments
Other Short-Term Assets	$3.100M	$7.348M
YoY Change	11.91%	409.92%
Inventory	$11.17M	$10.95M
Prepaid Expenses
Receivables	$12.07M	$9.966M
Other Receivables	$315.0K	$417.0K
Total Short-Term Assets	$52.89M	$52.68M
YoY Change	4.67%	-3.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.118M	$2.109M
YoY Change	-69.04%	-68.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.908M	$1.239M
YoY Change	50.35%	-5.71%
Total Long-Term Assets	$9.544M	$4.100M
YoY Change	6.68%	-49.91%
TOTAL ASSETS
Total Short-Term Assets	$52.89M	$52.68M
Total Long-Term Assets	$9.544M	$4.100M
Total Assets	$62.43M	$56.78M
YoY Change	4.97%	-9.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.658M	$1.905M
YoY Change	2.74%	-25.64%
Accrued Expenses	$7.009M	$6.757M
YoY Change	19.02%	8.09%
Deferred Revenue		$1.053M
YoY Change		38.74%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.892M	$8.778M
YoY Change	10361.18%	7467.24%
Total Short-Term Liabilities	$19.03M	$18.53M
YoY Change	67.63%	59.65%
LONG-TERM LIABILITIES
Long-Term Debt	$63.00K	$68.00K
YoY Change	-32.26%	423.08%
Other Long-Term Liabilities	$185.0K	$185.0K
YoY Change	30.28%	22.52%
Total Long-Term Liabilities	$185.0K	$185.0K
YoY Change	30.28%	22.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.03M	$18.53M
Total Long-Term Liabilities	$185.0K	$185.0K
Total Liabilities	$25.70M	$20.57M
YoY Change	93.09%	56.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.21M	-$39.22M
YoY Change	68.1%	112.04%
Common Stock	$35.00K	$35.00K
YoY Change	2.94%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.60M	$36.05M
YoY Change
Total Liabilities & Shareholders Equity	$62.43M	$56.78M
YoY Change	4.97%	-9.86%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$994.0K	-$3.483M
YoY Change	-81.68%	-41.41%
Depreciation, Depletion And Amortization	$151.0K	$203.0K
YoY Change	-38.87%	-9.78%
Cash From Operating Activities	-$4.852M	-$1.900M
YoY Change	-17.37%	-57.95%
INVESTING ACTIVITIES
Capital Expenditures	$156.0K	$110.0K
YoY Change	-138.9%	-60.57%
Acquisitions
YoY Change
Other Investing Activities	$7.267M
YoY Change
Cash From Investing Activities	$7.111M	-$110.0K
YoY Change	-1873.32%	-60.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	46.00K	$8.112M
YoY Change	2200.0%	8177.55%
NET CHANGE
Cash From Operating Activities	-4.852M	-$1.900M
Cash From Investing Activities	7.111M	-$110.0K
Cash From Financing Activities	46.00K	$8.112M
Net Change In Cash	2.305M	$6.063M
YoY Change	-136.76%	-230.78%
FREE CASH FLOW
Cash From Operating Activities	-$4.852M	-$1.900M
Capital Expenditures	$156.0K	$110.0K
Free Cash Flow	-$5.008M	-$2.010M
YoY Change	-8.46%	-58.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	0-12183
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road,
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
CY2023Q1	dei	City Area Code CityAreaCode	727
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	384-2323
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	APYX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34597822	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16255000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10192000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	359000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	668000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9966000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10602000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7752000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7545000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	417000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	99000	usd
CY2023Q1	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	428000	usd
CY2022Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	457000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	10946000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11797000	usd
CY2023Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4569000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2779000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2737000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	52684000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	42972000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2109000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6761000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	710000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	106000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	115000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1239000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1217000	usd
CY2023Q1	us-gaap	Assets Assets	56784000	usd
CY2022Q4	us-gaap	Assets Assets	51775000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1905000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2669000	usd
CY2023Q1	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7626000	usd
CY2022Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8928000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	184000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	33000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8778000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18526000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11850000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	448000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	470000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	68000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	73000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1343000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1408000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	185000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	181000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	20570000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13982000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34597822	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34597822	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75235000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73282000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39218000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35735000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	36052000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	37582000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	162000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	211000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36214000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37793000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56784000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51775000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12142000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12493000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4569000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4274000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	7573000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	8219000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1121000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1158000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	1740000	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	2286000	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	5068000	usd
CY2022Q1	us-gaap	Salaries And Wages SalariesAndWages	5181000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5255000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5465000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13184000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	14090000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5871000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	51000	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	2000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	234000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	8000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-21000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5799000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5898000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-5968000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-49000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3483000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5945000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54009000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	152000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1650000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-5968000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	49843000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37793000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1367000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	586000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36214000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-5968000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	203000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	225000	usd
CY2023Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	0	usd
CY2022Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	85000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-26000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1367000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1650000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-142000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	140000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	67000	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-837000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-475000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-858000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-649000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	207000	usd
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-879000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	371000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-776000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-51000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1435000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1378000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1881000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4518000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	110000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	279000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-279000	usd
CY2023Q1	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	0	usd
CY2022Q1	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	152000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9289000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1754000	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	586000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023Q1	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	9000	usd
CY2022Q1	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	54000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8112000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	98000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-58000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6063000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4636000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10192000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30870000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16255000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26234000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	8000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	125000	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-23600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20300000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1900000	usd
CY2023Q1	apyx	Sale Leaseback Term Of Lease SaleLeasebackTermOfLease	P10Y
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16300000	usd
CY2023Q1	apyx	Debt Instrument Covenant Cash And Cash Equivalents Balance DebtInstrumentCovenantCashAndCashEquivalentsBalance	10000000	usd
CY2023Q1	apyx	Sale Leaseback Purchase Agreement SaleLeasebackPurchaseAgreement	7650000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	200000	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.14
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	4388000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4979000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2331000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2160000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4655000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5115000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	11374000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	12254000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	428000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	457000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	10946000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11797000	usd
CY2023Q1	apyx	Sale Leaseback Renewal Term SaleLeasebackRenewalTerm	P5Y
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4956000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11295000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3387000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5041000	usd
CY2023Q1	apyx	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	1569000	usd
CY2022Q4	apyx	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	6254000	usd
CY2023Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	540000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	507000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2109000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6761000	usd
CY2023Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4569000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	usd
CY2023Q1	apyx	Sale Leaseback Purchase Agreement SaleLeasebackPurchaseAgreement	7650000	usd
CY2023Q1	apyx	Sale Leaseback Annual Rent Payment SaleLeasebackAnnualRentPayment	619500	usd
CY2023Q1	apyx	Sale Leaseback Annual Rent Increase SaleLeasebackAnnualRentIncrease	0.04
CY2023Q1	apyx	Sale Leaseback Management Fee On Rent Payment SaleLeasebackManagementFeeOnRentPayment	0.03
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	848000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	563000	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	570000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	usd
CY2023Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	790000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	847000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	368000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	391000	usd
CY2023Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1794000	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1825000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	924000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	901000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1053000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	853000	usd
CY2023Q1	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	345000	usd
CY2022Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	345000	usd
CY2023Q1	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	0	usd
CY2022Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	2079000	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	211000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	245000	usd
CY2023Q1	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	723000	usd
CY2022Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	879000	usd
CY2023Q1	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7626000	usd
CY2022Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8928000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year One DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne	49000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year Two DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo	60000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year Three DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree	70000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Cash And Cash Equivalents Balance DebtInstrumentCovenantCashAndCashEquivalentsBalance	10000000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	250000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.40
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P10Y
CY2023Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	1800000	usd
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	485000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	737000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	8778000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2778000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3333000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3333000	usd
CY2023Q1	apyx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	556000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	203000	usd
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	154000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3483000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3483000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5945000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5945000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34598000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34598000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34429000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34429000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1367000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1650000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6520444	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.12
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1408865	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	146164	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7783145	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.27
CY2023Q1	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	22654	shares
CY2023Q1	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	19013	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.858
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.391
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.012
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2100000	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	250000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	4000000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12142000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	51000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	234000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12493000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5871000	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	2000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	8000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-21000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2023Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.269
CY2022Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.396
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12142000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12493000	usd

Files In Submission

Name	View Source	Status
apyx-20230331_lab.xml	Edgar Link	unprocessable
0000719135-23-000027-index-headers.html	Edgar Link	pending
0000719135-23-000027-index.html	Edgar Link	pending
0000719135-23-000027.txt	Edgar Link	pending
0000719135-23-000027-xbrl.zip	Edgar Link	pending
a2023q110-kexhibit311.htm	Edgar Link	pending
a2023q110-kexhibit312.htm	Edgar Link	pending
a2023q110-kexhibit322.htm	Edgar Link	pending
a2023q110-qexhibit321.htm	Edgar Link	pending
apyx-20230331.htm	Edgar Link	pending
apyx-20230331.xsd	Edgar Link	pending
apyx-20230331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
apyx-20230331_pre.xml	Edgar Link	unprocessable
apyx-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
apyx-20230331_cal.xml	Edgar Link	unprocessable
apyx-20230331_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2023 Q2 Form 10-Q Financial Statement

#000071913523000027 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2023 Q2 Form 10-Q Financial Statement

#000071913523000027 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx